Repairing the broken market for antibiotic innovation

Health Affairs

Volumn 34, Issue 2, 2015, Pages 277-285

  Outterson, Kevin ^a,b,c   Powers, John H ^d   Daniel, Gregory W ^e   McClellan, Mark B ^f  

^a BOSTON UNIVERSITY   (United States)

^b ROYAL INSTITUTE OF INTERNATIONAL AFFAIRS   (United Kingdom)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e Engelberg Center for Health Care Reform at Brookings   (United States)

^f Health Care Innovation Value Initiative at the Engelberg Center for Health Care Reform at Brookings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BEDAQUILINE; CEFTOLOZANE PLUS TAZOBACTAM; DALBAVANCIN; FIDAXOMICIN; ORITAVANCIN; PRESCRIPTION DRUG; TEDIZOLID; VACCINE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CAPITAL; CLINICAL TRIAL (TOPIC); COMMERCIAL PHENOMENA; COMPETITION; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG USE; EUROPEAN MEDICINES AGENCY; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; INFECTION CONTROL; INVESTMENT; MEDICAL RESEARCH; METABOLIC DISORDER; MULTIDRUG RESISTANT TUBERCULOSIS; ORGANIZATION AND MANAGEMENT; PATIENT ADVOCACY; PRODUCT DEVELOPMENT; PUBLIC HEALTH SERVICE; PUBLIC-PRIVATE PARTNERSHIP; REIMBURSEMENT; UNCERTAINTY; VACCINATION; BACTERIAL INFECTIONS; DRUG APPROVAL; DRUG COST; DRUG EFFECTS; DRUG MANUFACTURE; ECONOMICS; FEE; INTERNATIONAL COOPERATION; LEGISLATION AND JURISPRUDENCE; MULTIDRUG RESISTANCE; ORGANIZATION; POSTMARKETING SURVEILLANCE; PUBLIC HEALTH; STANDARDS; TRENDS; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG COSTS; DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FINANCING, GOVERNMENT; HUMANS; INTERNATIONAL COOPERATION; ORGANIZATIONAL INNOVATION; ORPHAN DRUG PRODUCTION; PRESCRIPTION FEES; PRODUCT SURVEILLANCE, POSTMARKETING; PUBLIC HEALTH; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; REIMBURSEMENT, INCENTIVE; UNITED STATES;

EID: 84922701063     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1003     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013 [Internet]. Atlanta (GA): CDC; 2013 [cited 2014 Dec 23]. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
2. Outterson K. New business models for sustainable antibiotics [Internet]. London: Chatham House; 2014 Feb [cited 2014 Dec 23]. Available from: http://www.chathamhouse.org/sites/files/chathamhouse/public/Research/Global%20Health/0214SustainableAntibiotics.pdf
3. The White House. Executive Order 13676: combating antibioticresistant bacteria. Fed Regist. 2014 Sep 18;184(79):56931-5.
4. The White House. National strategy for combating antibiotic-resistant bacteria [Internet]. Washington (DC): The White House; 2014 Sep [cited 2014 Dec 29]. Available from: http://www.whitehouse.gov/sites/default/files/docs/carb_national_strategy.pdf
5. President's Council of Advisors on Science and Technology. Report to the President on combating antibiotic resistance [Internet]. Washington (DC): The White House; 2014 Sep [cited 2014 Dec 29]. Available from: http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST/pcast_carb_report_sept2014.pdf
6. Department of Health. Prime Minister warns of global threat of antibiotic resistance [Internet]. London: Department of Health; 2014 Jul 2 [cited 2014 Dec 23]. Available from: https://www.gov.uk/government/news/prime-minister-warns-ofglobal-threat-of-antibiotic-resistance
7. Innovative Medicines Initiative. ND4BB: new drugs for bad bugs [Internet]. Brussels: IMI; [cited 2014 Dec 23]. Available from: http://www.imi.europa.eu/content/nd4bb
8. World Health Organization. Antimicrobial resistance [Internet]. Geneva: WHO; 2014 May 24. Sixtyseventh World Health Assembly, WHA67.25, Agenda item 16.5; [cited 2014 Dec 23]. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R25-en.pdf
9. IMS Institute for Healthcare Informatics. Medicine use and shifting costs of healthcare: a review of the use of medicines in the US in 2013 [Internet]. Danbury (CT): IMS Health; 2014 Apr [cited 2014 Dec 23]. Available from: http://www.imshealth.com/portal/site/imshealth/menuitem.762a961826aad98f53c753c71ad8c22a/?vgnextoid=2684d47626745410VgnVCM10000076192ca2RCRD
10. Government Accountability Office. New drug approval: FDA's consideration of evidence from certain clinical trials [Internet].Washington (DC): GAO; 2010 Jul [cited 2014 Dec 23]. (Report No. GAO-10-798). Available from: http://www.gao.gov/assets/310/308301.pdf
11. Outterson K, Powers JH, Seoane-Vazquez E, Rodriguez-Monguio R, Kesselheim AS. Approval and withdrawal of new antibiotics and other antiinfectives in the U.S., 1980-2009. J Law Med Ethics. 2013; 41(3):688-96.
12. Kesselheim AS, Outterson K. Improving antibiotic markets for longterm sustainability. Yale J Health Policy Law Ethics. 2011;11(1):101-67.
13. Centers for Disease Control and Prevention. Office-related antibiotic prescribing for persons aged ≤ 14 years-United States, 1993-1994 to 2007-2008. Morb Mortal Wkly Rep. 2011;60(34):1153-6.
14. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, Craig AS, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3): 244-56.
15. Bragginton EC, Piddock LJ. UK and European Union public and charitable funding from 2008 to 2013 for bacteriology and antibiotic research in the UK: an observational study. Lancet Infect Dis. 2014;14(9): 857-68.
16. Projan SJ.Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6(5): 427-30.
17. Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, Outterson K. Analytical framework for examining the value of antibacterial products [Internet]. Washington (DC): Department of Health and Human Services; 2014 Apr [cited 2014 Dec 23]. Figure 4. Available from: http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm
18. Food and Drug Administration. Draft guidance for industry on antibacterial therapies for patients with unmet medical need for the treatment of serious bacterial diseases. Fed Regist. 2013 Jul 2;78(127): 39737-8.
19. Rex JH, Goldberger M, Eisenstein BI, Harney C. The evolution of the regulatory framework for antibacterial agents. Ann N Y Acad Sci. 2014;1323:11-21.
20. Frank C, Himmelstein DU, Woolhandler S, Bor DH, Wolfe SM, Heymann O, et al. Era of faster FDA drug approval has also seen increased black-box warnings and market withdrawals. Health Aff (Millwood). 2014;33(8):1453-59.
21. Ginsberg A. The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem. 2011;3(10): 1247-52.
22. Doshi P. US incentive scheme for neglected diseases: a good idea gone wrong? BMJ. 2014;349:g4665.
23. Ridley DR, Grabowski HG, Moe JL. Developing drugs for developing countries. Health Aff (Millwood). 2006;25(2): 313-24.
24. Food and Drug Administration. Establishing a list of qualifying pathogens under the Food and Drug Administration Safety and Innovation Act. Final rule. Fed Regist. 2014; 79(108):32464-81.
25. Centers for Medicare and Medicaid Services. Acute inpatient PPS [Internet]. Baltimore (MD): CMS; [cited 2014 Dec 23]. Available from: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/index.html
26. Centers for Medicare and Medicaid Services. New medical services and new technologies [Internet]. Baltimore (MD): CMS; [cited 2014 Dec 23]. Available from: http://www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatientPPS/newtech.html
27. Shah H, Tallman AM, Capurso S. Clarifications about add-on payments for fidaxomicin. Am J Health Syst Pharm. 2013;70(12):1015-6.
28. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364(5):422-31.
29. Kelly C, Karlin S. Antibiotic disincentives? Medicare decisions underscore limits of add-on payments [Internet]. New York (NY): Pink Sheet; 2014 Aug 18 [cited 2014 Dec 23]. Available from: https://www.pharmamedtechbi.com/publications/the-pink-sheet/76/33/antibiotic-emdisemincentivesmedicare-decisions-underscorelimits-of-addon-payments
30. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014; 370(23):2169-79.
31. Brookings Council on Antibacterial Drug Development. Incentives for change: addressing the challenges in antibacterial drug development meeting; 2013 Feb 27; Washington (DC): Engelberg Center for Health Care Reform at Brookings; 2013.
32. Anomaly J. Collective action and individual choice: rethinking how we regulate narcotics and antibiotics. J Med Ethics. 2013;39(12):752-6.
33. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742-50.